Which has stronger earnings & valuation, KYTX or BHVN?

Biohaven is trading at a lower price-to-earnings ratio than Kyverna Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kyverna Therapeutics N/A N/A -$161.31M -$3.28 N/A Biohaven N/A N/A -$738.82M -$5.67 N/A

Is KYTX or BHVN more profitable?

Kyverna Therapeutics' return on equity of -81.88% beat Biohaven's return on equity. Company Net Margins Return on Equity Return on Assets Kyverna Therapeutics N/A -81.88% -64.87% Biohaven N/A -866.46% -137.99%

Does the media refer more to KYTX or BHVN?

In the previous week, Biohaven had 1 more articles in the media than Kyverna Therapeutics. MarketBeat recorded 7 mentions for Biohaven and 6 mentions for Kyverna Therapeutics. Kyverna Therapeutics' average media sentiment score of 0.52 beat Biohaven's score of 0.35 indicating that Kyverna Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kyverna Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Biohaven 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings & valuation, PHVS or KYTX?

Pharvaris is trading at a lower price-to-earnings ratio than Kyverna Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pharvaris N/A N/A -$198.79M -$3.18 N/A Kyverna Therapeutics N/A N/A -$161.31M -$3.28 N/A

Is PHVS or KYTX more profitable?

Pharvaris' return on equity of -67.56% beat Kyverna Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Pharvaris N/A -67.56% -61.13% Kyverna Therapeutics N/A -81.88% -64.87%

Does the media prefer PHVS or KYTX?

In the previous week, Kyverna Therapeutics had 4 more articles in the media than Pharvaris. MarketBeat recorded 6 mentions for Kyverna Therapeutics and 2 mentions for Pharvaris. Pharvaris' average media sentiment score of 1.19 beat Kyverna Therapeutics' score of 0.52 indicating that Pharvaris is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pharvaris 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kyverna Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer OCUL or KYTX?

In the previous week, Kyverna Therapeutics had 2 more articles in the media than Ocular Therapeutix. MarketBeat recorded 6 mentions for Kyverna Therapeutics and 4 mentions for Ocular Therapeutix. Ocular Therapeutix's average media sentiment score of 0.91 beat Kyverna Therapeutics' score of 0.52 indicating that Ocular Therapeutix is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ocular Therapeutix 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kyverna Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to HRMY or KYTX?

In the previous week, Kyverna Therapeutics had 3 more articles in the media than Harmony Biosciences. MarketBeat recorded 6 mentions for Kyverna Therapeutics and 3 mentions for Harmony Biosciences. Harmony Biosciences' average media sentiment score of 1.18 beat Kyverna Therapeutics' score of 0.52 indicating that Harmony Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Harmony Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kyverna Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Kyverna Therapeutics (KYTX) Competitors

$7.94 +0.17 (+2.19%)

Closing price 07/14/2026 04:00 PM Eastern

Extended Trading

$8.11 +0.17 (+2.14%)

As of 07:29 AM Eastern

Compare

KYTX vs. ABCL, BHVN, PHVS, OCUL, and HRMY

Should you buy Kyverna Therapeutics stock or one of its competitors? MarketBeat compares Kyverna Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Kyverna Therapeutics include AbCellera Biologics (ABCL), Biohaven (BHVN), Pharvaris (PHVS), Ocular Therapeutix (OCUL), and Harmony Biosciences (HRMY). These companies are all part of the "pharmaceutical products" industry.

How does Kyverna Therapeutics compare to AbCellera Biologics?

Kyverna Therapeutics (NASDAQ:KYTX) and AbCellera Biologics (NASDAQ:ABCL) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, valuation, institutional ownership, media sentiment and earnings.

Kyverna Therapeutics presently has a consensus price target of $30.00, suggesting a potential upside of 277.83%. AbCellera Biologics has a consensus price target of $8.00, suggesting a potential upside of 18.69%. Given Kyverna Therapeutics' higher possible upside, equities analysts plainly believe Kyverna Therapeutics is more favorable than AbCellera Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyverna Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
AbCellera Biologics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

18.1% of Kyverna Therapeutics shares are owned by institutional investors. Comparatively, 61.4% of AbCellera Biologics shares are owned by institutional investors. 17.6% of Kyverna Therapeutics shares are owned by company insiders. Comparatively, 28.4% of AbCellera Biologics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Kyverna Therapeutics has a net margin of 0.00% compared to AbCellera Biologics' net margin of -181.75%. AbCellera Biologics' return on equity of -14.86% beat Kyverna Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kyverna Therapeutics	N/A	-81.88%	-64.87%
AbCellera Biologics	-181.75%	-14.86%	-10.62%

Kyverna Therapeutics has a beta of 1.87, suggesting that its share price is 87% more volatile than the broader market. Comparatively, AbCellera Biologics has a beta of 1.14, suggesting that its share price is 14% more volatile than the broader market.

AbCellera Biologics has higher revenue and earnings than Kyverna Therapeutics. AbCellera Biologics is trading at a lower price-to-earnings ratio than Kyverna Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kyverna Therapeutics	N/A	N/A	-$161.31M	-$3.28	N/A
AbCellera Biologics	$75.13M	27.40	-$146.41M	-$0.48	N/A

In the previous week, Kyverna Therapeutics had 5 more articles in the media than AbCellera Biologics. MarketBeat recorded 6 mentions for Kyverna Therapeutics and 1 mentions for AbCellera Biologics. AbCellera Biologics' average media sentiment score of 0.98 beat Kyverna Therapeutics' score of 0.52 indicating that AbCellera Biologics is being referred to more favorably in the news media.

Company	Overall Sentiment
Kyverna Therapeutics	Positive
AbCellera Biologics	Positive

Summary

AbCellera Biologics beats Kyverna Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Kyverna Therapeutics compare to Biohaven?

Kyverna Therapeutics (NASDAQ:KYTX) and Biohaven (NYSE:BHVN) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, analyst recommendations, valuation and dividends.

Kyverna Therapeutics has a beta of 1.87, meaning that its share price is 87% more volatile than the broader market. Comparatively, Biohaven has a beta of 1.28, meaning that its share price is 28% more volatile than the broader market.

18.1% of Kyverna Therapeutics shares are held by institutional investors. Comparatively, 88.8% of Biohaven shares are held by institutional investors. 17.6% of Kyverna Therapeutics shares are held by insiders. Comparatively, 13.8% of Biohaven shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Biohaven had 1 more articles in the media than Kyverna Therapeutics. MarketBeat recorded 7 mentions for Biohaven and 6 mentions for Kyverna Therapeutics. Kyverna Therapeutics' average media sentiment score of 0.52 beat Biohaven's score of 0.35 indicating that Kyverna Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kyverna Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Biohaven	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Biohaven is trading at a lower price-to-earnings ratio than Kyverna Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kyverna Therapeutics	N/A	N/A	-$161.31M	-$3.28	N/A
Biohaven	N/A	N/A	-$738.82M	-$5.67	N/A

Kyverna Therapeutics currently has a consensus target price of $30.00, indicating a potential upside of 277.83%. Biohaven has a consensus target price of $21.63, indicating a potential upside of 44.36%. Given Kyverna Therapeutics' higher probable upside, equities research analysts clearly believe Kyverna Therapeutics is more favorable than Biohaven.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyverna Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Biohaven	2 Sell rating(s)	4 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.67

Kyverna Therapeutics' return on equity of -81.88% beat Biohaven's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kyverna Therapeutics	N/A	-81.88%	-64.87%
Biohaven	N/A	-866.46%	-137.99%

Summary

Kyverna Therapeutics beats Biohaven on 9 of the 13 factors compared between the two stocks.

How does Kyverna Therapeutics compare to Pharvaris?

Pharvaris (NASDAQ:PHVS) and Kyverna Therapeutics (NASDAQ:KYTX) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, profitability, risk, analyst recommendations, dividends and media sentiment.

In the previous week, Kyverna Therapeutics had 4 more articles in the media than Pharvaris. MarketBeat recorded 6 mentions for Kyverna Therapeutics and 2 mentions for Pharvaris. Pharvaris' average media sentiment score of 1.19 beat Kyverna Therapeutics' score of 0.52 indicating that Pharvaris is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pharvaris	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kyverna Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

18.1% of Kyverna Therapeutics shares are owned by institutional investors. 17.6% of Kyverna Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Pharvaris is trading at a lower price-to-earnings ratio than Kyverna Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharvaris	N/A	N/A	-$198.79M	-$3.18	N/A
Kyverna Therapeutics	N/A	N/A	-$161.31M	-$3.28	N/A

Pharvaris has a beta of -2.34, suggesting that its share price is 334% less volatile than the broader market. Comparatively, Kyverna Therapeutics has a beta of 1.87, suggesting that its share price is 87% more volatile than the broader market.

Pharvaris currently has a consensus price target of $49.64, indicating a potential upside of 44.21%. Kyverna Therapeutics has a consensus price target of $30.00, indicating a potential upside of 277.83%. Given Kyverna Therapeutics' higher possible upside, analysts plainly believe Kyverna Therapeutics is more favorable than Pharvaris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharvaris	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Kyverna Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Pharvaris' return on equity of -67.56% beat Kyverna Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pharvaris	N/A	-67.56%	-61.13%
Kyverna Therapeutics	N/A	-81.88%	-64.87%

Summary

Kyverna Therapeutics beats Pharvaris on 7 of the 13 factors compared between the two stocks.

How does Kyverna Therapeutics compare to Ocular Therapeutix?

Ocular Therapeutix (NASDAQ:OCUL) and Kyverna Therapeutics (NASDAQ:KYTX) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, valuation, analyst recommendations, media sentiment and dividends.

Ocular Therapeutix has a beta of 0.88, suggesting that its stock price is 12% less volatile than the broader market. Comparatively, Kyverna Therapeutics has a beta of 1.87, suggesting that its stock price is 87% more volatile than the broader market.

Ocular Therapeutix currently has a consensus price target of $25.11, indicating a potential upside of 158.88%. Kyverna Therapeutics has a consensus price target of $30.00, indicating a potential upside of 277.83%. Given Kyverna Therapeutics' higher probable upside, analysts plainly believe Kyverna Therapeutics is more favorable than Ocular Therapeutix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ocular Therapeutix	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79
Kyverna Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, Kyverna Therapeutics had 2 more articles in the media than Ocular Therapeutix. MarketBeat recorded 6 mentions for Kyverna Therapeutics and 4 mentions for Ocular Therapeutix. Ocular Therapeutix's average media sentiment score of 0.91 beat Kyverna Therapeutics' score of 0.52 indicating that Ocular Therapeutix is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ocular Therapeutix	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kyverna Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Kyverna Therapeutics has lower revenue, but higher earnings than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Kyverna Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ocular Therapeutix	$51.95M	40.88	-$265.94M	-$1.46	N/A
Kyverna Therapeutics	N/A	N/A	-$161.31M	-$3.28	N/A

59.2% of Ocular Therapeutix shares are owned by institutional investors. Comparatively, 18.1% of Kyverna Therapeutics shares are owned by institutional investors. 3.1% of Ocular Therapeutix shares are owned by insiders. Comparatively, 17.6% of Kyverna Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Kyverna Therapeutics has a net margin of 0.00% compared to Ocular Therapeutix's net margin of -558.24%. Ocular Therapeutix's return on equity of -64.28% beat Kyverna Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ocular Therapeutix	-558.24%	-64.28%	-48.15%
Kyverna Therapeutics	N/A	-81.88%	-64.87%

Summary

Ocular Therapeutix beats Kyverna Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Kyverna Therapeutics compare to Harmony Biosciences?

Harmony Biosciences (NASDAQ:HRMY) and Kyverna Therapeutics (NASDAQ:KYTX) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, dividends, media sentiment, valuation, profitability, institutional ownership, risk and analyst recommendations.

Harmony Biosciences has a beta of 0.94, indicating that its stock price is 6% less volatile than the broader market. Comparatively, Kyverna Therapeutics has a beta of 1.87, indicating that its stock price is 87% more volatile than the broader market.

Harmony Biosciences has higher revenue and earnings than Kyverna Therapeutics. Kyverna Therapeutics is trading at a lower price-to-earnings ratio than Harmony Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harmony Biosciences	$868.45M	2.32	$158.69M	$2.48	14.04
Kyverna Therapeutics	N/A	N/A	-$161.31M	-$3.28	N/A

Harmony Biosciences presently has a consensus price target of $42.50, suggesting a potential upside of 22.09%. Kyverna Therapeutics has a consensus price target of $30.00, suggesting a potential upside of 277.83%. Given Kyverna Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Kyverna Therapeutics is more favorable than Harmony Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harmony Biosciences	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.50
Kyverna Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

86.2% of Harmony Biosciences shares are owned by institutional investors. Comparatively, 18.1% of Kyverna Therapeutics shares are owned by institutional investors. 11.0% of Harmony Biosciences shares are owned by company insiders. Comparatively, 17.6% of Kyverna Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Harmony Biosciences has a net margin of 16.20% compared to Kyverna Therapeutics' net margin of 0.00%. Harmony Biosciences' return on equity of 17.19% beat Kyverna Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Harmony Biosciences	16.20%	17.19%	11.99%
Kyverna Therapeutics	N/A	-81.88%	-64.87%

In the previous week, Kyverna Therapeutics had 3 more articles in the media than Harmony Biosciences. MarketBeat recorded 6 mentions for Kyverna Therapeutics and 3 mentions for Harmony Biosciences. Harmony Biosciences' average media sentiment score of 1.18 beat Kyverna Therapeutics' score of 0.52 indicating that Harmony Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Harmony Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kyverna Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Harmony Biosciences beats Kyverna Therapeutics on 10 of the 16 factors compared between the two stocks.

Get Kyverna Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KYTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KYTX vs. The Competition

Export

Metric	Kyverna Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$472.38M	$3.68B	$6.86B	$12.44B
Dividend Yield	N/A	2.19%	2.68%	8.42%
P/E Ratio	-2.42	20.98	26.96	24.38
Price / Sales	N/A	311.10	518.38	91.92
Price / Cash	N/A	143.66	48.59	59.36
Price / Book	2.06	8.54	10.90	6.33
Net Income	-$161.31M	$23.83M	$3.59B	$331.02M
7 Day Performance	-19.88%	-2.77%	-1.51%	-0.33%
1 Month Performance	-2.58%	5.85%	2.76%	-1.29%
1 Year Performance	107.85%	52.15%	28.54%	21.30%

Kyverna Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KYTX Kyverna Therapeutics	2.6507 of 5 stars	$7.94 +2.2%	$30.00 +277.8%	+80.9%	$472.38M	N/A	N/A	96
ABCL AbCellera Biologics	1.9349 of 5 stars	$7.70 -2.2%	$8.33 +8.2%	+59.0%	$2.35B	$75.13M	N/A	500	Gap Up
BHVN Biohaven	3.5653 of 5 stars	$15.59 -2.8%	$21.63 +38.7%	+5.6%	$2.35B	N/A	N/A	239
PHVS Pharvaris	3.9619 of 5 stars	$34.59 +4.1%	$49.64 +43.5%	+44.6%	$2.26B	N/A	N/A	30	Positive News High Trading Volume
OCUL Ocular Therapeutix	3.1967 of 5 stars	$10.33 +6.9%	$25.11 +143.1%	-13.9%	$2.26B	$51.95M	N/A	230

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KYTX) was last updated on 7/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Kyverna Therapeutics (KYTX) Competitors

KYTX vs. ABCL, BHVN, PHVS, OCUL, and HRMY

How does Kyverna Therapeutics compare to AbCellera Biologics?

Summary

How does Kyverna Therapeutics compare to Biohaven?

Summary

How does Kyverna Therapeutics compare to Pharvaris?

Summary

How does Kyverna Therapeutics compare to Ocular Therapeutix?

Summary

How does Kyverna Therapeutics compare to Harmony Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KYTX vs. The Competition

Kyverna Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Kyverna Therapeutics (KYTX) Competitors

KYTX vs. ABCL, BHVN, PHVS, OCUL, and HRMY

How does Kyverna Therapeutics compare to AbCellera Biologics?

Do analysts rate KYTX or ABCL?

Do insiders and institutionals hold more shares of KYTX or ABCL?

Is KYTX or ABCL more profitable?

Which has more volatility & risk, KYTX or ABCL?

Which has higher earnings and valuation, KYTX or ABCL?

Does the media refer more to KYTX or ABCL?

Summary

How does Kyverna Therapeutics compare to Biohaven?

Which has more risk and volatility, KYTX or BHVN?

Do insiders and institutionals believe in KYTX or BHVN?

Does the media refer more to KYTX or BHVN?

Which has stronger earnings & valuation, KYTX or BHVN?

Do analysts prefer KYTX or BHVN?

Is KYTX or BHVN more profitable?

Summary

How does Kyverna Therapeutics compare to Pharvaris?

Does the media prefer PHVS or KYTX?

Do institutionals & insiders have more ownership in PHVS or KYTX?

Which has higher earnings & valuation, PHVS or KYTX?

Which has more volatility & risk, PHVS or KYTX?

Do analysts recommend PHVS or KYTX?

Is PHVS or KYTX more profitable?

Summary

How does Kyverna Therapeutics compare to Ocular Therapeutix?

Which has more risk & volatility, OCUL or KYTX?

Do analysts recommend OCUL or KYTX?

Does the media prefer OCUL or KYTX?

Which has better earnings and valuation, OCUL or KYTX?

Do insiders and institutionals have more ownership in OCUL or KYTX?

Is OCUL or KYTX more profitable?

Summary

How does Kyverna Therapeutics compare to Harmony Biosciences?

Which has more volatility and risk, HRMY or KYTX?

Which has better valuation & earnings, HRMY or KYTX?

Do analysts prefer HRMY or KYTX?

Do institutionals and insiders hold more shares of HRMY or KYTX?

Is HRMY or KYTX more profitable?

Does the media refer more to HRMY or KYTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KYTX vs. The Competition

Kyverna Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools